DE123850T1 - Hemmung von tumorwachstum und metastase mit calciumkanal absperrenden verbindungen. - Google Patents

Hemmung von tumorwachstum und metastase mit calciumkanal absperrenden verbindungen.

Info

Publication number
DE123850T1
DE123850T1 DE198484102861T DE84102861T DE123850T1 DE 123850 T1 DE123850 T1 DE 123850T1 DE 198484102861 T DE198484102861 T DE 198484102861T DE 84102861 T DE84102861 T DE 84102861T DE 123850 T1 DE123850 T1 DE 123850T1
Authority
DE
Germany
Prior art keywords
compound
use according
lower alkyl
calcium channel
bay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198484102861T
Other languages
English (en)
Inventor
Kenneth V. Michigan 48236 Honn
John D. Detroit Michigan 48207 Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of DE123850T1 publication Critical patent/DE123850T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (15)

Europäische Patentanmeldung 84 102 861.6 Anmelder: THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY EP 1498 ' Patentansprüche
1. Verwendung einer Calciumkanalblockierverbindung oder eines pharmazeutisch annehmbaren Säureadditionsalzes hiervon zur Verringerung der Metastase und des neoplastischen Wachstums in einem Sauger.
2. Verwendung nach Anspruch 1, dadurch gekennzeichnet , daß die Verbindung ein in 4-Stellung substituiertes 1,4-Dihydropyridin ist.
3. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Verbindung 1,4-Dihydro-2,6-dimethyl-4-(3'-nitrophenyl)-pyridin-3-(niederalkylester)-5-(niederalkylester) ist, wobei das Niederalkyl 1 bis 6 Kohlenstoffatome enthält.
4. Verwendung nach Anspruch 1, dadurch gekennzeichnet , daß die Verbindung Nifedipin (BAY a 1040) ist.
5. Verwendung nach Anspruch 1, dadurch gekennzeichnet , daß die Calciumkanalblockierverbindung Nimodipin (BAY e 9736) ist.
6. Verwendung nach Anspruch 2, dadurch gekennzeichnet , daß die Verabreichung oral erfolgt.
7. Verwendung nach Anspruch 1, dadurch gekennzeichnet , daß die Verbindung Verapamil oder Diltiazem ist.
8. Verwendung nach Anspruch 1, dadurch gekennzeichnet , daß die Metastase und das neopla-
stische Wachstum durch das amelanotische B-16-Melanom in Mäusen erzeugt worden ist.
9. Verfahren zum Prüfen auf die Verhinderung der durch Tumorzellen induzierten Blutplättchen-Aggregation, umfassend das Einbringen,in vitro, zu gewählten Blutplättchen und Tumorzellen, die aggregieren, einer wirksamen Menge einer Calciumkanalblockier-Vasodilatorverbindung oder eines pharmazeutisch annehmbaren Säureadditionsalzes hiervon, um die Verbindung auf die Inhibierung der Blutplättchen-Aggregation mit den gewählten Tumorzellen zu prüfen.
10. Verfahren nach Anspruch 9, dadurch g e k e η η -
zeichnet, daß die Verbindung ein in 4-Stellung substituiertes 1 ,4-Dihydropyridin ist.
11. Verfahren nach Anspruch 9, dadurch gekennzeichnet , daß die Verbindung 1 , 4~Dihydro~2 , 6- dimethyl-4-(3'-nitrophenyl)-pyridin~3-(niederalkylester) ist, wobei das Niederalkyl 1 bis 6 Koh.lenstoffatome enthält.
12. Verfahren nach Anspruch 9, dadurch g e k e η η -
zeichnet, daß die Verbindung Nifedipin (BAY a 1040) ist.
13- Verfahren nach Anspruch 9, dadurch gekennzeichnet , daß die Verbindung Nirnodipin (BAY e 9736) ist.
14. Verfahren nach Anspruch 9, dadurch g e k e η η .zeichnet , daß die Verbindung Verapamil ist.,
15. Verfahren nach Anspruch 9, dadurch g e k e η η zeichnet, daßdie Verbindung Dilfciazem ist.
DE198484102861T 1983-03-31 1984-03-15 Hemmung von tumorwachstum und metastase mit calciumkanal absperrenden verbindungen. Pending DE123850T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/480,704 US4690935A (en) 1983-03-31 1983-03-31 Inhibition of tumor growth and metastasis with calcium channel blocker compounds

Publications (1)

Publication Number Publication Date
DE123850T1 true DE123850T1 (de) 1985-02-14

Family

ID=23909011

Family Applications (1)

Application Number Title Priority Date Filing Date
DE198484102861T Pending DE123850T1 (de) 1983-03-31 1984-03-15 Hemmung von tumorwachstum und metastase mit calciumkanal absperrenden verbindungen.

Country Status (5)

Country Link
US (1) US4690935A (de)
EP (1) EP0123850A3 (de)
JP (1) JPS606613A (de)
CA (1) CA1223820A (de)
DE (1) DE123850T1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906646A (en) * 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
JPH0753665B2 (ja) * 1984-04-20 1995-06-07 財団法人癌研究会 抗転移剤
US5326772A (en) * 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
IT1201454B (it) * 1985-08-19 1989-02-02 Boehringer Biochemia Srl 1,4-diidropiridine-2-sostituite
IE59777B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
AT387518B (de) * 1985-12-18 1989-02-10 Bayer Ag Verfahren zur herstellung von fluessigen spruehpraeparaten von dihydropyridinen
DE3610037A1 (de) * 1986-03-21 1987-09-24 Schering Ag Nifedipinkombinationspraeparat
DE3635931A1 (de) * 1986-10-22 1988-04-28 Basf Ag Wirkstoffe zur verhuetung von tumormetastasen
IT1213440B (it) * 1986-12-24 1989-12-20 Boehringer Biochemia Srl 2-ditioalchil-diidropiridine, un metodo per la loro preparazione e composizioni farmaceutiche chele contengono.
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
DE3705117A1 (de) * 1987-02-18 1988-09-01 Goedecke Ag Verwendung von benzothiazepin-derivaten, insbesondere diltiazem bei der protektion von lymphozyten
US4954436A (en) * 1987-08-06 1990-09-04 Trustees Of Dartmouth College Dihydropyridine-sensitive calcium channel as a tumor associated marker
HU206181B (en) * 1988-02-19 1992-09-28 Byk Gulden Lomberg Chem Fab Process for producing pharmaceutical compositions comprising optically pure r-(+)-niguldipin and its derivatives and suitable for treating tumoros diseases
US5216172A (en) * 1988-02-24 1993-06-01 Ajinomoto Co., Inc. 1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates useful as agents against drug resistant tumor cells
EP0330470A3 (de) * 1988-02-24 1992-01-02 Ajinomoto Co., Inc. Gegen Tumorzellen verwendbare 1,4-Dihydropyridin-Derivate
ES2059767T3 (es) * 1988-07-28 1994-11-16 Nikken Chemicals Co Ltd Derivado de 1,4-dihidropiridina.
EP0353692B1 (de) * 1988-08-02 1995-10-04 Nissan Chemical Industries Ltd. Mittel zur Verbesserung von Arzneimitteleffekten für Antitumormittel
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
CA2030160A1 (en) * 1989-11-22 1991-05-23 Nahed K. Ahmed Benzothiazepine metastasis treatment
CA2030159A1 (en) * 1989-11-22 1991-05-23 Nahed K. Ahmed Anti-cancer drug potentiators
US5001236A (en) * 1989-11-22 1991-03-19 Marion Laboratories, Inc. Benzothiazepines
AU7579291A (en) * 1990-04-16 1991-11-11 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Use of purinergic receptor agonists as antineoplastic agents
US5242692A (en) * 1990-07-10 1993-09-07 Bar Ilan University Anti-metastatic factor
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
EP0511790A1 (de) * 1991-04-26 1992-11-04 Ajinomoto Co., Inc. Gegen Tumorzellen verwendbare 1,4-Dihydropyridinderivate
GB9119983D0 (en) * 1991-09-19 1991-11-06 Erba Carlo Spa Dihydropyridine derivatives useful in antitumor therapy
WO1994003470A1 (en) * 1992-08-10 1994-02-17 Davies Richard J Method and apparatus for screening and diagnosing for cancers
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US20040167165A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
GB201318659D0 (en) * 2013-10-22 2013-12-04 Ucl Business Plc Beta-catenin
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US20210205310A1 (en) * 2018-05-25 2021-07-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
JPH0753665B2 (ja) * 1984-04-20 1995-06-07 財団法人癌研究会 抗転移剤

Also Published As

Publication number Publication date
JPS606613A (ja) 1985-01-14
EP0123850A3 (de) 1989-04-26
CA1223820A (en) 1987-07-07
US4690935A (en) 1987-09-01
EP0123850A2 (de) 1984-11-07

Similar Documents

Publication Publication Date Title
DE123850T1 (de) Hemmung von tumorwachstum und metastase mit calciumkanal absperrenden verbindungen.
CA1045138A (en) Unsymmetrical esters of n-substituted 1,4-dihydropyridine 3,5-dicarboxylic acid
KR920009822A (ko) 피페리디닐캄포설포닐 옥시토신 길항제
JPS55301A (en) 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its preparation
Towart et al. Effects of unsymmetrical ester substituted 1, 4-dihydropyridine derivatives and their optical isomers on contraction of smooth muscle
BG100154A (en) Carbazole derivatibes having inhibiting effect to 17,20-lyase
ES8700856A1 (es) Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina
GB1455502A (en) 1,4-dihydropyridine derivatives
ES8500264A1 (es) Procedimiento para la fabricacion de 4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridinas
EP0031801A3 (de) Hypotensiv wirksame, in 6-Stellung substituierte 4-(2',3'-Dichlorphenyl)-2-methyl-1,4-dihydropyridin-3,5-dicarbonsäurediester, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
KR860000286A (ko) 디히드로피리딘 유도체의 제조방법
EP0191724A3 (de) 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
PL253328A1 (en) Method of obtaining novel derivatives of 1,4-dihydropyridine
JPS56140989A (en) 1,4-dihydrophyridine-3,5-dicarboxylic ester derivative or its salt
DE3689213D1 (de) 2-(Heteroalkyl)-1,4-dihydropyridine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
KR940009180A (ko) 4-헤테로시클릴 치환 디히드로피리딘
KR880011099A (ko) 피리딘 유도체, 이의 제조방법, 이 유도체를 함유하는 간 손상치료 및 예방제, 및 이 약제를 사용하여 간 손상을 치료 및 예방하는 방법
JPS57167967A (en) 1,4-dihydropyridine-3,5-dicarboxylic acid ester or its salt
KR840002824A (ko) N-옥사이드 화합물의 제조방법
JPS5718674A (en) Carbostyril derivative
JPS57200364A (en) 1,4-dihydropyridine-3,5-dicarboxylic ester derivative and its salt